Traw Pharma director granted 14,150 stock options

Q: What stock option grant did Traw Pharma (TRAW) report for John Harold Leaman?

Traw Pharma reported that director John Harold Leaman received 14,150 stock options to buy common shares at an exercise price of $0.6800 per share, as part of his equity compensation package under the 2021 Incentive Compensation Plan.

Q: What are the vesting terms of John Harold Leaman’s options at TRAW?

The stock options granted to John Harold Leaman will vest 100% on July 9, 2027, the first anniversary of the July 9, 2026 grant date, providing a single cliff-vesting schedule rather than gradual vesting over multiple years.

Q: What is the exercise price and expiration date of the TRAW options granted to Leaman?

Leaman’s stock options carry an exercise price of $0.6800 per share and are scheduled to expire on July 9, 2036. He may choose to exercise them after vesting and before that expiration date, subject to plan terms.

Q: How many derivative securities does John Harold Leaman hold after this TRAW grant?

Following the grant, John Harold Leaman holds 14,150 derivative securities directly, all represented by this single stock option award for an equal number of underlying Traw Pharma common shares, according to the reported post-transaction holdings data.

Q: Under which plan were John Harold Leaman’s TRAW stock options granted?

The options were awarded under Traw Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The grant was approved by the company’s compensation committee, which the disclosure describes as being comprised of independent directors.

Traws Pharma, Inc. director John Harold Leaman received a grant of 14,150 stock options to buy common stock at an exercise price of $0.6800 per share.

Accepted by SEC EDGAR 07/14/2026 - 08:19 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Traws Pharma, Inc. director John Harold Leaman received a grant of 14,150 stock options to buy common stock at an exercise price of $0.6800 per share. Granted under the 2021 Incentive Compensation Plan, these options vest 100% on July 9, 2027 and expire on July 9, 2036, leaving Leaman holding 14,150 derivative securities directly.

Insider Trade Summary

Grant/Award: 14,150 shares

Grant/Award 1 txn

Insider Leaman John Harold

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) ^F1	14,150	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 14,150 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 14,150 contracts (Direct)

Footnotes (1)

F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Key Figures

Stock options granted: 14,150 shares Exercise price: $0.6800 per share Vesting date: July 9, 2027 +2 more

5 metrics

Stock options granted 14,150 shares Stock Option (right to buy) award on July 9, 2026

Exercise price $0.6800 per share Conversion or exercise price for the stock options

Vesting date July 9, 2027 Options vest 100% on the first anniversary of the grant date

Expiration date July 9, 2036 Expiration of the stock option award

Post-transaction derivative holdings 14,150 options Total derivative securities held directly after the grant

Key Terms

Stock Option (right to buy), 2021 Incentive Compensation Plan, vest 100%, conversion or exercise price

4 terms

Stock Option (right to buy) financial

"Security title reported as Stock Option (right to buy) for this grant"

2021 Incentive Compensation Plan financial

"Awarded under the Issuer's 2021 Incentive Compensation Plan, as amended"

vest 100% financial

"The stock options under this award will vest 100% on the first anniversary"

conversion or exercise price financial

"Conversion or exercise price reported as 0.6800 for the stock options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option grant did Traw Pharma (TRAW) report for John Harold Leaman?

Traw Pharma reported that director John Harold Leaman received 14,150 stock options to buy common shares at an exercise price of $0.6800 per share, as part of his equity compensation package under the 2021 Incentive Compensation Plan.

What are the vesting terms of John Harold Leaman’s options at TRAW?

The stock options granted to John Harold Leaman will vest 100% on July 9, 2027, the first anniversary of the July 9, 2026 grant date, providing a single cliff-vesting schedule rather than gradual vesting over multiple years.

What is the exercise price and expiration date of the TRAW options granted to Leaman?

Leaman’s stock options carry an exercise price of $0.6800 per share and are scheduled to expire on July 9, 2036. He may choose to exercise them after vesting and before that expiration date, subject to plan terms.

How many derivative securities does John Harold Leaman hold after this TRAW grant?

Following the grant, John Harold Leaman holds 14,150 derivative securities directly, all represented by this single stock option award for an equal number of underlying Traw Pharma common shares, according to the reported post-transaction holdings data.

Under which plan were John Harold Leaman’s TRAW stock options granted?

The options were awarded under Traw Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The grant was approved by the company’s compensation committee, which the disclosure describes as being comprised of independent directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leaman John Harold

(Last)

(First)

(Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN

PENNSYLVANIA

18940

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.68	07/09/2026		A		14,150		07/09/2027⁽¹⁾	07/09/2036	Common Stock	14,150	$0	14,150	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ John H. Leaman	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR